ALDH5A1 and succinic semialdehyde dehydrogenase deficiency: Ablation of SSADH activity, the second enzyme in the conversion of GABA to succinic acid (Figure 1), results in a neurometabolic disorder whose nonspecific neurological morbidity associates with accumulation of GABA and the GABA derivative γ‐hydroxybutyric acid (GHB), the latter a GABA analogue.3 Based upon the prediction that GHB in central nervous system (CNS) will decrease with VGB intake, it is often employed empirically in SSADHD.